The US Food and Drug Administration (FDA) has ordered manufacturers of popular GLP-1 medicines to add warnings about a rare eye condition that can cause sudden and potentially permanent vision loss. The warning concerns non-arteritic anterior ischaemic optic neuropathy (NAION), a condition in which reduced blood flow damages the optic nerve. It can lead to sudden, painless vision loss, usually in one eye. The medicines affected include Ozempic, Wegovy, Mounjaro and Zepbound. The FDA's requirement applies to all medicines with GLP-1 receptor agonist activity, not just these four brands. In its safety communication dated November 9, the FDA said its review found a potential increased risk of rare NAION events among people taking these medicines. An analysis of 126 clinical trials, involving more than 134,000 participants, recorded 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases among people receiving comparator treatments. However, the findings do not establish that the medicines directly cause the condition. The American Academy of Ophthalmology has also said that any additional risk appears small and that a cause-and-effect relationship has not been established. The FDA has advised patients to seek immediate medical attention if they experience sudden vision loss, blurred vision, blind spots or changes in colour perception in one eye. The agency said patients who develop NAION should discuss whether to continue their medication with a healthcare professional. Doctors are advised to consider stopping the drug if the condition is diagnosed, unless its benefits clearly outweigh the risks. Novo Nordisk, the maker of Ozempic and Wegovy, said available data do not establish a cause-and-effect relationship. Eli Lilly, which makes Mounjaro and Zepbound, said it was reviewing the FDA's update.
FDA Orders Rare Eye Condition Warning on GLP-1 Drugs
The US FDA has ordered manufacturers of GLP-1 medicines to add warnings about a potential increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The warning applies to medicines used for diabetes and weight management.


0 comments
No comments yet. Yours would be the first.